Get started
Author

Nuno Couto

Observed names: N Couto, N. Couto, N., Couto
ORCID: 0000-0002-9553-3189
Observed ORCID: 0000-0002-9553-3189
OpenAlex ID: A5000522256
Exosome-Based Cell-Cell Communication in the Tumor Microenvironment
2018 · Joana Maia, Sergio Caja, et al. · Frontiers in Cell and Developmental Biology · 666
PDF
Tachykinin receptors antagonism for asthma: a systematic review
2011 · Renata Ramalho, Raquel Soares, et al. · BMC Pulmonary Medicine · 56
PDF
Employing Flow Cytometry to Extracellular Vesicles Sample Microvolume Analysis and Quality Control
2020 · Joana Maia, Silvia Batista, et al. · Frontiers in Cell and Developmental Biology · 55
PDF
Exosomes as emerging players in cancer biology
2018 · Nuno Couto, Sergio Caja, et al. · Biochimie · 52
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
2025 · Alessandro Audisio, Chiara Gallio, et al. · JAMA Oncology · 28
PDF
Treatment optimization of locally advanced and metastatic pancreatic cancer (Review)
2021 · Anabela Barros, Catarina Pulido, et al. · International Journal of Oncology · 17
PDF
The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective
2019 · Silvia Batista, Ana C. Gregório, et al. · Journal of Oncology · 17
PDF
Establishment of Pancreatobiliary Cancer Zebrafish Avatars for Chemotherapy Screening
2021 · Mariana Tavares Barroso, Bruna Costa, et al. · Cells · 15
PDF
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers
2025 · Margherita Rimini, Lorenzo Fornaro, et al. · Liver International · 13
PDF
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC ‐D Index
2025 · Mara Persano, Margherita Rimini, et al. · Liver International · 11
PDF
IgG+ Extracellular Vesicles Measure Therapeutic Response in Advanced Pancreatic Cancer
2022 · Nuno Couto, Julia Elzanowska, et al. · Cells · 11
PDF
International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set
2024 · Robert Samuel, Stephen R. Knight, et al. · EClinicalMedicine · 8
PDF
Neutropenia and cutaneous lesions secondary to propafenone
2009 · Nuno Couto, Márcia Ferreira, et al. · European Journal of Dermatology · 6
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population
2025 · Federica Lo Prinzi, Francesca Salani, et al. · International Journal of Cancer · 5
Prognostic value of unrelated atypical serum immunofixation patterns during Multiple Myeloma therapy
2012 · Cristina Guimarães, Rui Bergantim, et al. · Journal of Hematology & Oncology · 5
PDF
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study
2025 · Margherita Rimini, Lorenzo Fornaro, et al. · International Journal of Cancer · 4
PDF
FOENIX-CCA4: A phase 2 study of futibatinib 20 mg and 16 mg in patients with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor 2 (FGFR2) fusions/rearrangements.
2024 · Teresa Macarulla, Takashi Mizuno, et al. · Journal of Clinical Oncology · 4
Population Analysis of Extracellular Vesicles in Microvolumes of Biofluids
2020 · Joana Maia, Silvia Batista, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 4
Pancreatic intraductal papillary mucinous neoplasm associated colloid carcinoma
2021 · Beatriz Flor-de-Lima, Patrícia S․ Freitas, et al. · Radiology Case Reports · 3
PDF
Omega-3 therapeutic supplementation in a patient with metastatic adenocarcinoma of the pancreas with muscle mass depletion
2017 · R Ramalho, P Ramalho, et al. · European Journal of Clinical Nutrition · 3
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy
2025 · Francesco Vitiello, Caterina Vivaldi, et al. · Oncology · 2
Retrospective multicenter cohort of nab-paclitaxel plus gemcitabine (NG) after FOLFIRINOX failure in advanced pancreatic cancer (APC): Effectiveness, tolerability, and response markers.
2017 · Ines Vendrell, Arlindo Rebelo Ferreira, et al. · Journal of Clinical Oncology · 2
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real‐World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab
2026 · Margherita Rimini, Angela Lamarca, et al. · International Journal of Cancer · 1
Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysis
2026 · S. Camera, A. Vogel, et al. · ESMO Open · 1
Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study
2024 · Javier Trujillo-Santos, Ignacio García-Escobar, et al. · The Oncologist · 1
Works count: 40
Citation count: 991
H-index: 11
I10-index: 11
Year
Topic
Type